|
1
|
Teglund S and Toftgård R: Hedgehog beyond
medulloblastoma and basal cell carcinoma. Biochim Biophys Acta.
1805:181–208. 2010.PubMed/NCBI
|
|
2
|
Varjosalo M and Taipale J: Hedgehog:
Functions and mechanisms. Genes Dev. 22:2454–2472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marini KD, Payne BJ, Watkins DN and
Martelotto LG: Mechanisms of Hedgehog signalling in cancer. Growth
Factors. 29:221–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jeng KS, Chang CF and Lin SS: Sonic
Hedgehog signaling in organogenesis, tumors, and tumor
microenvironments. Int J Mol Sci. 21:7582020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lauth M, Bergström A, Shimokawa T, Tostar
U, Jin Q, Fendrich V, Guerra C, Barbacid M and Toftgård R:
DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling
by mutant RAS. Nat Struct Mol Biol. 17:718–725. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stecca B, Mas C, Clement V, Zbinden M,
Correa R, Piguet V, Beermann F, Ruiz IA and Altaba A: Melanomas
require HEDGEHOG-GLI signaling regulated by interactions between
GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA.
104:5895–5900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Riobó NA, Lu K, Ai X, Haines GM and
Emerson CP Jr: Phosphoinositide 3-kinase and Akt are essential for
Sonic Hedgehog signaling. Proc Natl Acad Sci USA. 103:4505–4510.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mangelberger D, Kern D, Loipetzberger A,
Eberl M and Aberger F: Cooperative Hedgehog-EGFR signaling. Front
Biosci (Landmark Ed). 17:90–99. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Faião-Flores F, Alves-Fernandes DK,
Pennacchi PC, Sandri S, Vicente AL, Scapulatempo-Neto C, Vazquez
VL, Reis RM, Chauhan J, Goding CR, et al: Targeting the hedgehog
transcription factors GLI1 and GLI2 restores sensitivity to
vemurafenib-resistant human melanoma cells. Oncogene. 36:1849–1861.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Santini R, Pietrobono S, Pandolfi S,
Montagnani V, D'Amico M, Penachioni JY, Vinci MC, Borgognoni L and
Stecca B: SOX2 regulates self-renewal and tumorigenicity of human
melanoma-initiating cells. Oncogene. 33:4697–4708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pandolfi S, Montagnani V, Lapucci A and
Stecca B: HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and
function and regulates melanoma cell growth. Cell Death Differ.
22:2006–2019. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nieto MA: The snail superfamily of
zinc-finger transcription factors. Nat Rev Mol Cell Biol.
3:155–166. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cohen ME, Yin M, Paznekas WA, Schertzer M,
Wood S and Jabs EW: Human SLUG gene organization, expression, and
chromosome map location on 8q. Genomics. 51:468–471. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pérez-Mancera PA, González-Herrero I,
Maclean K, Turner AM, Yip MY, Sánchez-Martín M, García JL, Robledo
C, Flores T, Gutiérrez-Adán A, et al: SLUG (SNAI2) overexpression
in embryonic development. Cytogenet Genome Res. 114:24–29. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The role of snail in EMT and tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bolós V, Peinado H, Pérez-Moreno MA, Fraga
MF, Esteller M and Cano A: The transcription factor Slug represses
E-cadherin expression and induces epithelial to mesenchymal
transitions: A comparison with Snail and E47 repressors. J Cell
Sci. 116:499–451. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wels C, Joshi S, Koefinger P, Bergler H
and Schaider H: Transcriptional activation of ZEB1 by Slug leads to
cooperative regulation of the epithelial-mesenchymal
transition-like phenotype in melanoma. J Invest Dermatol.
131:1877–1885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Casas E, Kim J, Bendesky A, Ohno-Machado
L, Wolfe CJ and Yang J: Snail2 is an essential mediator of
Twist1-induced epithelial mesenchymal transition and metastasis.
Cancer Res. 71:245–254. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brabletz S, Schuhwerk H, Brabletz T and
Stemmler MP: Dynamic EMT: A multi-tool for tumor progression. EMBO
J. 40:e1086472021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pérez-Mancera PA, González-Herrero I,
Pérez-Caro M, Gutiérrez-Cianca N, Flores T, Gutiérrez-Adán A,
Pintado B, Sánchez-Martín M and Sánchez-García I: SLUG in cancer
development. Oncogene. 24:3073–3082. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cobaleda C, Pérez-Caro M, Vicente-Dueñas C
and Sánchez-García I: Function of the zinc-finger transcription
factor SNAI2 in cancer and development. Annu Rev Genet. 41:41–61.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barbato L, Bocchetti M, Di Biase A and
Regad T: Cancer stem cells and targeting strategies. Cells.
8:9262019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fenouille N, Tichet M, Dufies M, Pottier
A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari
A, et al: The epithelial-mesenchymal transition (EMT) regulatory
factor SLUG (SNAI2) is a downstream target of SPARC and AKT in
promoting melanoma cell invasion. PLoS One. 7:e403782012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo Q, Ning F, Fang R, Wang HS, Zhang G,
Quan MY, Cai SH and Du J: Endogenous Nodal promotes melanoma
undergoing epithelial-mesenchymal transition via Snail and Slug in
vitro and in vivo. Am J Cancer Res. 5:2098–2112. 2015.PubMed/NCBI
|
|
25
|
Pearlman RL, Montes de Oca MK, Pal HC and
Afaq F: Potential therapeutic targets of epithelial-mesenchymal
transition in melanoma. Cancer Lett. 391:125–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arienti C, Tesei A, Carloni S, Ulivi P,
Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R and
Zoli W: SLUG silencing increases radiosensitivity of melanoma cells
in vitro. Cell Oncol (Dordr). 36:131–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gupta PB, Kuperwasser C, Brunet JP,
Ramaswamy S, Kuo WL, Gray JW, Naber SP and Weinberg RA: The
melanocyte differentiation program predisposes to metastasis after
neoplastic transformation. Nat Genet. 37:1047–1054. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shirley SH, Greene VR, Duncan LM, Torres
Cabala CA, Grimm EA and Kusewitt DF: Slug expression during
melanoma progression. Am J Pathol. 180:2479–2489. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Caramel J, Papadogeorgakis E, Hill L,
Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J,
Hutchinson P, Tse G, et al: A switch in the expression of embryonic
EMT-inducers drives the development of malignant melanoma. Cancer
Cell. 24:466–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gunarta IK, Li R, Nakazato R, Suzuki R,
Boldbaatar J, Suzuki T and Yoshioka K: Critical role of
glioma-associated oncogene homolog 1 in maintaining invasive and
mesenchymal-like properties of melanoma cells. Cancer Sci.
108:1602–1611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vlčková K, Ondrušová L, Vachtenheim J,
Réda J, Dundr P, Zadinová M, Žáková P and Poučková P: Survivin, a
novel target of the Hedgehog/GLI signaling pathway in human tumor
cells. Cell Death Dis. 7:e20482016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vlčková K, Vachtenheim J, Réda J, Horák P
and Ondrušová L: Inducibly decreased MITF levels do not affect
proliferation and phenotype switching but reduce differentiation of
melanoma cells. J Cell Mol Med. 22:2240–2251. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miller AJ, Du J, Rowan S, Hershey CL,
Widlund HR and Fisher DE: Transcriptional regulation of the
melanoma prognostic marker melastatin (TRPM1) by MITF in
melanocytes and melanoma. Cancer Res. 64:509–516. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sánchez-Martín M, Rodríguez-García A,
Pérez-Losada J, Sagrera A, Read AP and Sánchez-García I: SLUG
(SNAI2) deletions in patients with Waardenburg disease. Hum Mol
Genet. 11:3231–3236. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sánchez-Martín M, Pérez-Losada J,
Rodríguez-García A, González-Sánchez B, Korf BR, Kuster W, Moss C,
Spritz RA and Sánchez-García I: Deletion of the SLUG (SNAI2) gene
results in human piebaldism. Am J Med Genet A. 122A:125–132. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Goodall J, Carreira S, Denat L, Kobi D,
Davidson I, Nuciforo P, Sturm RA, Larue L and Goding CR: Brn-2
represses microphthalmia-associated transcription factor expression
and marks a distinct subpopulation of microphthalmia-associated
transcription factor-negative melanoma cells. Cancer Res.
68:7788–7794. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roessler E, Ermilov AN, Grange DK, Wang A,
Grachtchouk M, Dlugosz AA and Muenke M: A previously unidentified
amino-terminal domain regulates transcriptional activity of
wild-type and disease-associated human GLI2. Hum Mol Genet.
14:2181–2188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kumasaka M, Sato S, Yajima I, Goding CR
and Yamamoto H: Regulation of melanoblast and retinal pigment
epithelium development by Xenopus laevis Mitf. Dev Dyn.
234:523–534. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vachtenheim J and Drdová B: A dominant
negative mutant of microphthalmia transcription factor (MITF)
lacking two transactivation domains suppresses transcription
mediated by wild type MITF and a hyperactive MITF derivative.
Pigment Cell Res. 17:43–50. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dynek JN, Chan SM, Liu J, Zha J,
Fairbrother WJ and Vucic D: Microphthalmia-associated transcription
factor is a critical transcriptional regulator of melanoma
inhibitor of apoptosis in melanomas. Cancer Res. 68:3124–3132.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ikram MS, Neill GW, Regl G, Eichberger T,
Frischauf AM, Aberger F, Quinn A and Philpott M: GLI2 is expressed
in normal human epidermis and BCC and induces GLI1 expression by
binding to its promoter. J Invest Dermatol. 122:1503–1509. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Parent AE, Choi C, Caudy K, Gridley T and
Kusewitt DF: The developmental transcription factor slug is widely
expressed in tissues of adult mice. J Histochem Cytochem.
52:959–965. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Müller J, Krijgsman O, Tsoi J, Robert L,
Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes
Foppen MH, et al: Low MITF/AXL ratio predicts early resistance to
multiple targeted drugs in melanoma. Nat Commun. 5:57122014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tanno B, Sesti F, Cesi V, Bossi G,
Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B and
Raschellà G: Expression of Slug is regulated by c-Myb and is
required for invasion and bone marrow homing of cancer cells of
different origin. J Biol Chem. 285:29434–29445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Miao Y, Zhang W, Liu S, Leng X, Hu C and
Sun H: HOXC10 promotes growth and migration of melanoma by
regulating Slug to activate the YAP/TAZ signaling pathway. Discov
Oncol. 12:122021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Das S, Harris LG, Metge BJ, Liu S, Riker
AI, Samant RS and Shevde LA: The hedgehog pathway transcription
factor GLI1 promotes malignant behavior of cancer cells by
up-regulating osteopontin. J Biol Chem. 284:22888–22897. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang ZR and Yang N: MiR-33a-5p inhibits
the growth and metastasis of melanoma cells by targeting SNAI2.
Neoplasma. 67:813–824. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Alexaki VI, Javelaud D, Van Kempen LC,
Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS,
Fournier PJ, et al: GLI2-mediated melanoma invasion and metastasis.
J Natl Cancer Inst. 102:1148–1159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu X, Hu Y, Yu B, Peng K and Gan X: CRKL
is a critical target of Hh-GLI2 pathway in lung adenocarcinoma. J
Cell Mol Med. 25:6280–6288. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim YH, Kwei KA, Girard L, Salari K, Kao
J, Pacyna-Gengelbach M, Wang P, Hernandez-Boussard T, Gazdar AF,
Petersen I, et al: Genomic and functional analysis identifies CRKL
as an oncogene amplified in lung cancer. Oncogene. 29:1421–1430.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Weiss JM, Hunter MV, Cruz NM, Baggiolini
A, Tagore M, Ma Y, Misale S, Marasco M, Simon-Vermot T, Campbell
NR, et al: Anatomic position determines oncogenic specificity in
melanoma. Nature. 604:354–361. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang L, Huang J, Hu Y, Lu P, Luo Q and
Wang L: Gli promotes tumor progression through regulating
epithelial-mesenchymal transition in non-small-cell lung cancer. J
Cardiothorac Surg. 15:182020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chun HW and Hong R: Significance of the
hedgehog pathway-associated proteins Gli-1 and Gli-2 and the
epithelial-mesenchymal transition-associated proteins Twist and
E-cadherin in hepatocellular carcinoma. Oncol Lett. 3:1753–1762.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang L, Jin JQ, Zhou Y, Tian Z, Jablons DM
and He B: Gli is activated and promotes epithelial-mesenchymal
transition in human esophageal adenocarcinoma. Oncotarget.
9:853–865. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim JE, Leung E, Baguley BC and Finlay GJ:
Heterogeneity of expression of epithelial-mesenchymal transition
markers in melanocytes and melanoma cell lines. Front Oncol.
4:972013.
|
|
56
|
Davies MA and Kopetz S: Overcoming
resistance to MAPK pathway inhibitors. J Natl Cancer Inst.
105:9–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Vachtenheim J and Ondrušová L: Many
distinct ways lead to drug resistance in BRAF- and NRAS-mutated
melanomas. Life (Basel). 11:4242021.PubMed/NCBI
|
|
58
|
Vlčková K, Réda J, Ondrušová L, Krayem M,
Ghanem G and Vachtenheim J: GLI inhibitor GANT61 kills melanoma
cells and acts in synergy with obatoclax. Int J Oncol. 49:953–960.
2016. View Article : Google Scholar : PubMed/NCBI
|
